Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	7.22	8.33	15.45	2.5	-	-
Revenue Growth (YoY)	-48.97%	-46.07%	517.55%	-	-	-
Gross Profit	7.22	8.33	15.45	2.5	-	-
Selling, General & Admin	30.03	28.95	30.05	37.36	41.32	11.11
Research & Development	60.91	66	56.78	91.17	131.94	31.89
Operating Expenses	90.94	94.95	86.83	128.53	173.27	43
Operating Income	-83.71	-86.62	-71.37	-126.03	-173.27	-43
Interest Expense	-0.09	-0.1	-5	-3.8	-1.43	-0.03
Interest & Investment Income	6.57	6.94	3.57	0.25	0.17	0.05
Other Non Operating Income (Expenses)	0.36	-0.09	-34.77	-0.02	-	-17.03
EBT Excluding Unusual Items	-76.87	-79.88	-107.57	-129.59	-174.52	-60.01
Asset Writedown	-4.84	-4.84	-1.07	-36.42	-	-
Other Unusual Items	-5.06	-4.58	-2.94	-	-	-
Pretax Income	-86.77	-89.3	-111.57	-166.01	-174.52	-60.01
Net Income	-86.77	-89.3	-111.57	-166.01	-174.52	-60.01
Net Income to Common	-86.77	-89.3	-111.57	-166.01	-174.52	-60.01
Shares Outstanding (Basic)	260	250	116	44	38	18
Shares Outstanding (Diluted)	260	250	116	44	38	18
Shares Change (YoY)	64.21%	115.41%	164.20%	16.74%	113.13%	83.53%
EPS (Basic)	-0.33	-0.36	-0.96	-3.78	-4.64	-3.40
EPS (Diluted)	-0.33	-0.36	-0.96	-3.78	-4.64	-3.40
Free Cash Flow	-84.06	-81.6	-76.89	-109.01	-132.35	-30.81
Free Cash Flow Per Share	-0.32	-0.33	-0.66	-2.48	-3.52	-1.74
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	-
Operating Margin	-1158.80%	-1039.49%	-461.94%	-5037.05%	-	-
Profit Margin	-1201.08%	-1071.62%	-722.06%	-6635.25%	-	-
Free Cash Flow Margin	-1163.61%	-979.23%	-497.62%	-4356.88%	-	-
EBITDA	-82.51	-85.38	-70	-124.86	-172.78	-42.99
D&A For EBITDA	1.2	1.25	1.37	1.17	0.49	0.01
EBIT	-83.71	-86.62	-71.37	-126.03	-173.27	-43

Updated May 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q